Literature DB >> 23385622

[Emergency treatment and management of anaphylaxis].

K Brockow1, J Ring.   

Abstract

Anaphylaxis, the maximal manifestation of an immediate allergic reaction, is a life-threatening systemic reaction. The immediate therapy is chosen according to the clinical manifestations and new German guidelines are in preparation. Required measures include immediate removal of allergen, adequate positioning, assessment of severity and organ involvement and activation of emergency medical services. In anaphylaxis with primarily cardiovascular involvement, epinephrine is the treatment of choice and given together with volume substitution, oxygen, H(1)-antihistamines and corticosteroids. Obstruction of the airways is treated with intramuscular and inhaled epinephrine, or alternatively β(2)-sympathicomimetics, and oxygen. Abdominal or cutaneous involvement, such as generalized urticaria, usually can be treated with intravenous H(1)-antihistamines, glucocorticoids and surveillance. In patients with anaphylaxis, the elicitor of the reaction has to be diagnosed by allergy testing. Patients with sustained risk for anaphylaxis should receive a self-medication kit and should be educated about behavioral patterns needed for prophylaxis and therapy of anaphylactic reactions. Patient educational intervention increases knowledge about anaphylaxis, and practical competence and thus, is a basis of a successful management of anaphylaxis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23385622     DOI: 10.1007/s00105-012-2453-5

Source DB:  PubMed          Journal:  Hautarzt        ISSN: 0017-8470            Impact factor:   0.751


  18 in total

1.  Sublingual immunotherapy for peanut allergy: clinical and immunologic evidence of desensitization.

Authors:  Edwin H Kim; J Andrew Bird; Michael Kulis; Susan Laubach; Laurent Pons; Wayne Shreffler; Pamela Steele; Janet Kamilaris; Brian Vickery; A Wesley Burks
Journal:  J Allergy Clin Immunol       Date:  2011-02-01       Impact factor: 10.793

2.  Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis.

Authors:  Melody C Carter; Jamie A Robyn; Peter B Bressler; John C Walker; Gail G Shapiro; Dean D Metcalfe
Journal:  J Allergy Clin Immunol       Date:  2007-05-03       Impact factor: 10.793

3.  High omalizumab dose controls recurrent reactions to venom immunotherapy in indolent systemic mastocytosis.

Authors:  K Kontou-Fili
Journal:  Allergy       Date:  2008-03       Impact factor: 13.146

4.  [Allergy--triggers of life-threatening and fatal anaphylaxis].

Authors:  K Brockow; J Ring
Journal:  MMW Fortschr Med       Date:  2006-07-20

5.  Oral peanut immunotherapy in children with peanut anaphylaxis.

Authors:  Katharina Blumchen; Helen Ulbricht; Ute Staden; Kerstin Dobberstein; John Beschorner; Lucila Camargo Lopes de Oliveira; Wayne G Shreffler; Hugh A Sampson; Bodo Niggemann; Ulrich Wahn; Kirsten Beyer
Journal:  J Allergy Clin Immunol       Date:  2010-06-12       Impact factor: 10.793

Review 6.  Epinephrine and its use in anaphylaxis: current issues.

Authors:  Keith J Simons; F Estelle R Simons
Journal:  Curr Opin Allergy Clin Immunol       Date:  2010-08

Review 7.  Anaphylaxis to radiographic contrast media.

Authors:  Knut Brockow; Johannes Ring
Journal:  Curr Opin Allergy Clin Immunol       Date:  2011-08

Review 8.  Anaphylaxis: acute treatment and management.

Authors:  Johannes Ring; Martine Grosber; Matthias Möhrenschlager; Knut Brockow
Journal:  Chem Immunol Allergy       Date:  2010-06-01

9.  Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium.

Authors:  Hugh A Sampson; Anne Muñoz-Furlong; Ronna L Campbell; N Franklin Adkinson; S Allan Bock; Amy Branum; Simon G A Brown; Carlos A Camargo; Rita Cydulka; Stephen J Galli; Jane Gidudu; Rebecca S Gruchalla; Allen D Harlor; David L Hepner; Lawrence M Lewis; Phillip L Lieberman; Dean D Metcalfe; Robert O'Connor; Antonella Muraro; Amanda Rudman; Cara Schmitt; Debra Scherrer; F Estelle R Simons; Stephen Thomas; Joseph P Wood; Wyatt W Decker
Journal:  J Allergy Clin Immunol       Date:  2006-02       Impact factor: 10.793

10.  Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients.

Authors:  K Brockow; C Jofer; H Behrendt; J Ring
Journal:  Allergy       Date:  2008-02       Impact factor: 13.146

View more
  1 in total

Review 1.  [Allergic emergencies].

Authors:  A-C Herr; T Biedermann; K Brockow
Journal:  Hautarzt       Date:  2018-05       Impact factor: 0.751

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.